ASH 2022 | Analysis of real-world outcomes in patients with B-ALL receiving tisagenlecleucel
Sara Ghorashian, PhD, MD, FRCP, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, shares some insights into a real-world dataset which was used to analyze the outcomes of patients with B-cell acute lymphoblastic leukemia (B-ALL) treated with tisagenlecleucel (tisa-cel). Dr Ghorashian explains the unique way in which this dataset was analyzed and the valuable information it provided to clinicians and patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis: Honoraria, Speakers Bureau; UCLB: Patents & Royalties.
